<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257500</url>
  </required_header>
  <id_info>
    <org_study_id>834422</org_study_id>
    <nct_id>NCT04257500</nct_id>
  </id_info>
  <brief_title>Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS</brief_title>
  <acronym>RING-PCOS</acronym>
  <official_title>Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Roe, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study to determine the metabolic effects of the contraceptive vaginal ring&#xD;
      among overweight and obese women with polycystic ovary syndrome (PCOS). We will recruit a&#xD;
      total of 40 participants and study use of the vaginal ring over a 4-month period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Metabolic Syndrome</measure>
    <time_frame>4 months</time_frame>
    <description>Metabolic Syndrome defined according to the updated Adult Treatment Panel III as 3 or more of the following criteria: blood pressure ≥130/85 mm Hg, waist circumference &gt;35 inches, fasting glucose ≥110 mg/dL, TG ≥150 mg/dL, HDL-C &lt;50 mg/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in low-density lipoprotein (LDL) measure</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high-density lipoprotein (HDL) measure</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglycerides measure</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apolipoprotein A</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apolipoprotein B</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in advanced lipid testing measure</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cholesterol efflux capacity</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin level</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting 2 hour oral Glucose Tolerance Test result</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Testosterone</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ferriman-Gallwey Hirsutism score</measure>
    <time_frame>4 months</time_frame>
    <description>A lower score indicates less hirsutism. The F-G scoring system has a minimum value of 0, and a maximum value of 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scoring on the Center for Epidemiologic Studies Depression Scale</measure>
    <time_frame>4 months</time_frame>
    <description>The range of values is zero to 60, with the higher scores indicating the presence of more depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scoring on the State-Trait Anxiety Inventory</measure>
    <time_frame>4 months</time_frame>
    <description>The State-Trait Anxiety Inventory measures both state and trait anxiety, the scores range from 20 to 80, with higher scores correlating with greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scoring on Polycystic Ovary Syndrome Quality of Life Questionnaire</measure>
    <time_frame>4 months</time_frame>
    <description>Worse quality of life is associated with a lower score on the questionnaire, with a range score from 30 to 210.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Contraceptive Ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing), which releases 120 mcg of etonogestrel and 15 mcg of ethinyl estradiol daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel/ethinyl estradiol vaginal ring</intervention_name>
    <description>16 weeks of continuous use of contraceptive vaginal ring</description>
    <arm_group_label>Contraceptive Ring</arm_group_label>
    <other_name>NuvaRing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PCOS according to Rotterdam criteria, with at least 2 of 3 of the&#xD;
             following criteria: oligomenorrhea (≤8 periods per year), clinical or biochemical&#xD;
             hyperandrogenism, and polycystic ovaries on ultrasound&#xD;
&#xD;
          -  Body mass index ≥25 and ≤45 kg/m2&#xD;
&#xD;
          -  In good general health according to the investigators' discretion&#xD;
&#xD;
          -  Willing to avoid pregnancy for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy or desire for pregnancy during course of study&#xD;
&#xD;
          -  Current breastfeeding&#xD;
&#xD;
          -  Second-trimester pregnancy within four weeks prior to initiation of NuvaRing or&#xD;
             third-trimester pregnancy within 6 months prior to initiation of NuvaRing&#xD;
&#xD;
          -  Use of hormonal contraception within four weeks prior to initiation of NuvaRing&#xD;
&#xD;
          -  Diagnosis of metabolic syndrome. Metabolic syndrome will be defined according to the&#xD;
             updated Adult Treatment Panel III as 3 or more of the following criteria: blood&#xD;
             pressure ≥130/85 mm Hg, waist circumference &gt;35 inches, fasting glucose ≥110 mg/dL, TG&#xD;
             ≥150 mg/dL, HDL-C &lt;50 mg/dL.&#xD;
&#xD;
          -  Contraindications to NuvaRing use:&#xD;
&#xD;
               -  Age ≥ 35 plus tobacco use&#xD;
&#xD;
               -  Current or past deep vein thrombosis or pulmonary embolism&#xD;
&#xD;
               -  Cerebrovascular disease&#xD;
&#xD;
               -  Coronary artery disease&#xD;
&#xD;
               -  Thrombogenic valvular or rhythm diseases of the heart (such as subacute bacterial&#xD;
                  endocarditis with valvular disease or atrial fibrillation)&#xD;
&#xD;
               -  Inherited or acquired coagulopathy&#xD;
&#xD;
               -  Headaches with focal neurological symptoms or migraine headaches with aura&#xD;
&#xD;
               -  Age ≥ 35 plus any migraine headaches&#xD;
&#xD;
               -  Liver tumors, benign or malignant&#xD;
&#xD;
               -  Undiagnosed abnormal uterine bleeding&#xD;
&#xD;
               -  Current or past breast cancer or other estrogen- or progestin-sensitive cancer&#xD;
&#xD;
               -  Hypersensitivity to any of the components of NuvaRing&#xD;
&#xD;
               -  Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir&#xD;
&#xD;
          -  Medical comorbidities:&#xD;
&#xD;
               -  21-hydroxylase deficiency, congenital adrenal hyperplasia&#xD;
&#xD;
               -  Untreated thyroid disease&#xD;
&#xD;
               -  Untreated hyperprolactinemia&#xD;
&#xD;
               -  Type 1 or 2 diabetes mellitus&#xD;
&#xD;
               -  Uncontrolled liver disease&#xD;
&#xD;
               -  Uncontrolled renal disease&#xD;
&#xD;
               -  Current alcohol abuse&#xD;
&#xD;
               -  Hypertension ≥ 140 mm Hg average systolic or ≥ 90 mm Hg average diastolic in&#xD;
                  women using anti-hypertensive medication&#xD;
&#xD;
               -  Hypertension ≥ 150 mm Hg average systolic or ≥ 100 mm Hg average diastolic in&#xD;
                  women not using anti-hypertensive medication&#xD;
&#xD;
               -  History of or current gynecologic cancer&#xD;
&#xD;
               -  Triglycerides &gt;=250 mg/dL&#xD;
&#xD;
               -  Current use of lipid-lowering or weight loss agents&#xD;
&#xD;
               -  Participation in any study of an investigational drug or device or biologic agent&#xD;
                  within 30 days&#xD;
&#xD;
               -  Suspected adrenal or ovarian tumor secreting androgens&#xD;
&#xD;
               -  Suspected Cushing's syndrome&#xD;
&#xD;
               -  Bariatric surgery within 12 months&#xD;
&#xD;
               -  Other medical concerns that in the judgment of the investigator may compromise&#xD;
                  safety of the participant or confound the reliability of compliance and&#xD;
                  information acquired in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Roe, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Morley</last_name>
    <phone>215-615-4202</phone>
    <email>andrea.morley@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Ruiz</last_name>
      <email>elizabeth.ruiz@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Roe, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Andrea Roe, MD, MPH</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>NuvaRing</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

